Evidence map›Paper›PMID 40599769›Full record

ArticleFrontiers in immunology2025

Interferons and

Benjamin Geiller, Camila Cevallos, Iuliia Tsybenko, Lydia Arnoux, Marie-Paule Felder-Schmittbuhl, Alexander W Pfaff

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Benjamin GeillerUR 3073 Pathogens Host Arthropods Vectors Interface, Toxoplasmosis Immunology Team, Université de Strasbourg, Strasbourg, France.
Camila CevallosUR 3073 Pathogens Host Arthropods Vectors Interface, Toxoplasmosis Immunology Team, Université de Strasbourg, Strasbourg, France.
Iuliia TsybenkoUR 3073 Pathogens Host Arthropods Vectors Interface, Toxoplasmosis Immunology Team, Université de Strasbourg, Strasbourg, France.
Lydia ArnouxUR 3073 Pathogens Host Arthropods Vectors Interface, Toxoplasmosis Immunology Team, Université de Strasbourg, Strasbourg, France.
Marie-Paule Felder-SchmittbuhlCentre National de la Recherche Scientifique, Institut des Neurosciences Cellulaires et Intégratives (UPR 3212), Université de Strasbourg, Strasbourg, France.
Alexander W PfaffUR 3073 Pathogens Host Arthropods Vectors Interface, Toxoplasmosis Immunology Team, Université de Strasbourg, Strasbourg, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The apicomplexan parasite Methods: We first investigated the mechanisms of PD-L1 regulation and the roles of type I and III interferons in an Results: Our findings reveal new roles for type I and III interferons in regulating glial cell activation and PD-L1 expression in RPE, Müller, astrocytes and microglial cells. Notably, Müller cells, the most abundant glial cells in the retina, showed the highest baseline PD-L1 expression at both the mRNA and protein levels, and responded robustly to interferon stimulation. This points to a more prominent immunoregulatory role for Müller cells in the retina than previously recognized. Furthermore, we identified a parasite protease-dependent mechanism that reduces PD-L1 expression in our Discussion: The parasite

Indexed as

B7-H1 AntigenBlood-Retinal BarrierInterferonsPeptide HydrolasesToxoplasmaToxoplasmosis, OcularAnimalsAstrocytesDisease Models, AnimalHumansMiceMice, Inbred C57BLMicrogliaRetinaRetinal Pigment EpitheliumB7-H1 AntigenCD274 protein, humanCd274 protein, mouseInterferonsPeptide Hydrolasesimmune privilegeinterferonsocular toxoplasmosisPD-L1retinaToxoplasma gondii

Identifiers

PMID40599769
PMCPMC12209286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.